- Alimera Sciences (ALIM +13.5%) says it has begun shipping the first orders of Iluvien to U.K. NHS facilities.
- The company also says "the first NHS patient received an implant for the treatment of DME" on January 10.
- For reference: NICE guidance allows for patients with a pseudophakic eye to receive Iluvien when their chronic DME is "considered insufficiently responsive to available therapies." (PR)
First Iluvien orders shipped to U.K.
Jan 13 2014, 09:48 ET